Genkyotex SA
Small molecule NOX inhibitors for diabetic neuropathy
This article was originally published in Start Up
Executive Summary
Genkyotex SA, named after Geneva, Kyoto and Texas, the locations of three of the academic founders, is developing small molecules that specifically inhibit NOX enzymes. Its lead product is a selective and orally available NOX1/4 inhibitor and is a first-in-class molecule. The initial target for this product is diabetic nephropathy, but the company believes it has potential in a range of other disorders in areas of unmet medical need, including in atherosclerosis, ophthalmological diseases involving angiogenesis such as retinopathy and wet age-related macular degeneration, and fibrosis. The agent has orphan drug status in the EU and the US for the treatment of idiopathic pulmonary fibrosis.